Abstract:Background Clinical guidelines for treatment decision in NPC are mainly based on the anatomical classification by UICC TNM staging. The concentration of plasma EBV DNA measured after radiotherapy (RT) or chemoradiation (CRT) is highly prognostic and independent of UICC stage, which may be useful in risk stratification of NPC patients to adjuvant therapy. Methods For model development, we used the prospective multi-center 0502 EBV DNA screening cohort (recruitment period 2006 - 2015; n = 745). Eligible patients had histologically confirmed NPC of stage II-IVB (UICC 7th Edition) and post-RT EBV DNA measured in plasma, no loco-regional disease or distant metastasis after RT/CRT and received no adjuvant therapy. Primary endpoint was overall survival (OS). We used recursive-partitioning analysis (RPA) to classify patients into groups of low-, intermediate- and high-risk of death. For internal validation, we pooled independent patient cohorts from previous published biomarker studies (1997-2006; n = 340). For external validation, we used external cohort of NPC patients treated at Sun Yat-sen University Cancer Center (2009 - 2012; n = 837) using SYSU EBV DNA test. Results RPA classified NPC patients based on the post-RT plasma EBV DNA level and UICC stage into three distinct prognostic groups (Table). RPA low risk group shared similar 5-yr OS (89.4%; 95% CI = 86.4-92.5%) as UICC stage II (88.5%; 84.0-93.1%) but included 2.3x number of patients that could be potentially spared of adjuvant therapy toxicity. The overall C-index of OS was 0.7118 for RPA risk group, compared to 0.6042 for TNM stage and 0.6747 for EBV DNA (both p < 0.01). RPA risk group has improved hazard discrimination and calibration than either TNM stage or plasma EBV DNA level. The result was validated in both internal and external cohorts. Table 287O Table Patient No. (%) 5-yr OS HR (95% C.I.) P UICC TNM stage (7th Ed) 1) Stage II 209 (28.1) 88.5 - 2) Stage III 368 (49.4) 81.0 1.50 (0.99-2.25) 0.054 3) Stage IVAB 168 (22.6) 69.4 3.01 (1.97-4.59) <0.0001 Post-RT plasma EBV DNA (copies/ml) 1) 0 573 (76.9) 87.3 - 2) 1-49 74 (9.9) 83.2 1.32 (0.76-2.27) 0.3259 3) 50-499 59 (7.9) 50.5 3.85 (2.55-5.81) <0.0001 4) > =500 39 (5.2) 28.3 11.59 (7.60-17.67) <0.0001 RPA risk group 1) Low risk EBV DNA 0 and stage II/III 1-49 and stage II 483 (64.8) 89.4 - 2) Intermediate risk EBV DNA 0 and stage IVAB 1-49 and stage III/IVAB 50-499 and stage II 176 (23.6) 78.5 2.40 (1.65-3.50) <0.0001 3) High risk EBV DNA 50-499 and stage III/IVAB >500 and any stage 86 (11.5) 37.2 8.54 (5.93-12.29) <0.0001 Conclusions Incorporation of post-RT plasma EBV DNA level into UICC TNM stage improved risk stratification of NPC patients to adjuvant therapy. Clinical trial identification Identifier: NCT00370890. Legal entity responsible for the study Comprehensive Cancer Trials Unit, Department of Clinical Oncology, The Chinese University of Hong Kong. Funding Has not received any funding. Disclosure E.P. Hui: Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Speaker Bureau / Expert testimony: Merck Serono; Research grant / Funding (institution): Pfizer. W.K.J. Lam: Shareholder / Stockholder / Stock options: Grail. K.C.A. Chan: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Grail; Leadership role, Shareholder / Stockholder / Stock options: Take2; Leadership role, Shareholder / Stockholder / Stock options: DRA. Y.M.D. Lo: Advisory / Consultancy, Leadership role, Shareholder / Stockholder / Stock options: Grail; Leadership role, Shareholder / Stockholder / Stock options: Take2 Health; Leadership role, Shareholder / Stockholder / Stock options: DRA. A.T.C. Chan: Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Merck Sharp & Dohme. All other authors have declared no conflicts of interest.

The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads

Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.

Combined pre-treatment and middle-treatment Epstein–Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients

The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area

Adjuvant Chemotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Long-term Results of a Phase 3 Multicentre Randomised Controlled Trial

Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer

The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort

Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy

Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort

Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era

Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy

Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis

The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study

A phase 2 Randomised Controlled Trial of Adjuvant Tumor-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients

Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level

Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA

Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy

Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.